Vijaya Diagnostic Centre directors cease tenure on completion

Vijaya Diagnostic Centre Limited has informed the stock exchanges that Mr. Shekhar Prasad Singh and Mr. Satyanaryana Murthy Chavali have ceased to be Non-Executive Independent Directors of the company. The cessation is effective from the close of business hours on May 25, 2026, following the completion of their respective tenures. The company acknowledged the valuable services rendered by the directors during their term.

The disclosure was submitted to the National Stock Exchange of India Limited and BSE Limited pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The filing included detailed disclosures in accordance with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026.

Details of the Change

The regulatory filing confirmed that the primary reason for the cessation for both directors was the completion of their tenure.

Particulars	Mr. Shekhar Prasad Singh	Mr. Satyanaryana Murthy Chavali
Reason for Change	Cessation due to tenure completion	Cessation due to tenure completion
Date of Cessation	May 25, 2026 (Closing of business hours)	May 25, 2026 (Closing of business hours)

Directorship and Committee Positions

The filing outlined the directorships and committee positions held by the outgoing directors in other listed entities. Mr. Shekhar Prasad Singh held no directorships or committee positions in listed companies. Mr. Satyanaryana Murthy Chavali held significant roles in Gland Pharma Limited.

Particulars	Mr. Shekhar Prasad Singh	Mr. Satyanaryana Murthy Chavali
Directorship in Listed Companies	Nil	Gland Pharma Limited
Committee Position(s)	Nil	Audit Committee (Chairman), Nomination & Remuneration Committee (Chairman), Stakeholders Relationship Committee & Share Transfer Committee (Chairman), ESOP Compensation Committee (Chairman)

The company confirmed that there are no other material reasons for the cessation beyond the completion of tenure.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+3.73%	+2.89%	+17.67%	+29.69%	+36.99%	+111.01%

Vijaya Diagnostic Centre has strengthened its board governance by appointing Mr. Satyanaryana Murthy Chavali and Mr. Dipinder Singh Sekhon as Non-Executive Independent Directors. The appointments, effective May 26, 2026, are for terms of five and two years respectively and are subject to shareholder approval. The decision was taken via a circular resolution by the Board of Directors.

Director Profiles and Tenures

The new directors bring extensive experience in pharmaceuticals and technology to the Vijaya Diagnostic Centre board. Mr. Chavali has been appointed for a five-year term, while Mr. Sekhon will serve for two years. Both appointments comply with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Particulars	Mr. Satyanaryana Murthy Chavali	Mr. Dipinder Singh Sekhon
DIN	00142138	01000924
Capacity	Non-Executive Independent Director	Non-Executive Independent Director
Term	5 years	2 years
Effective Date	May 26, 2026	May 26, 2026

Background and Expertise

Mr. Satyanaryana Murthy Chavali holds a Bachelor of Technology from the Indian Institute of Technology Madras and a Post Graduate Diploma in Management from the Indian Institute of Management Bangalore. He previously served as the Chief Executive Officer of Aurigene Discovery Technologies Limited and held senior leadership roles at Dr. Reddy's Laboratories Limited. His expertise spans pharmaceutical research, drug discovery, and corporate governance.

Mr. Dipinder Singh Sekhon is a technology entrepreneur and AI strategist with over two decades of experience in artificial intelligence and medical imaging. He is the Founder of iKITES.ai and Ophthal.ai. An alumnus of the Indian Institute of Technology Delhi, he has co-founded KritiKal Solutions and is associated with the Foundation for Innovation and Technology Transfer (FITT).

Regulatory Disclosures

The company confirmed that neither appointee is related to any existing director on the Board. Furthermore, both individuals are not debarred from holding the office of director pursuant to any SEBI order or any other authority. The detailed disclosures were made in accordance with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026.